Capsular serotyping was done by

bexA PCR and capsule type-specific PCRs for bexA positive isolates as described previously [35], with modifications to the HI-1, HI-2 and f3 primers. A new serotype e-specific reverse primer and a bexA probe were designed for this study (Table 2). Susceptibility testing MIC determination by microbroth dilution (HTM, Oxoid Ltd, Basingstoke, UK) was carried out according to CLSI guidelines [36], except that testing of penicillin-beta-lactamase inhibitor combinations was performed with fixed inhibitor concentrations [37]. Beta-lactam agents tested were ampicillin, amoxicillin, piperacillin, cefuroxime, cefotaxime (Sigma-Aldrich, St. Louis, MO, USA) and meropenem (Sequoia, Veliparib molecular weight Pangbourne, UK). For beta-lactamase positive isolates, ampicillin,

amoxicillin and piperacillin MICs were determined in the presence of sulbactam 4 mg/L (Sequoia), clavulanate 2 mg/L and tazobactam 4 mg/L (Sigma-Aldrich), respectively. MICs were within accepted ranges for H. influenzae ATCC 49247 (rPBP3) and H. influenzae ATCC 49766 FK506 (sPBP3), and within the wild type range (http://​www.​eucast.​org/​MIC_​distributions) for H. influenzae ATCC 35056 (TEM-1 positive). MICs were interpreted according to EUCAST clinical breakpoints, except for piperacillin and piperacillin-tazobactam where breakpoints are not defined [37]. Meningitis breakpoints were used for susceptibility categorization of meropenem to allow quantification of low-level resistance. Data from this study are included in the EUCAST database for MIC distributions of clinical isolates. Resistance genotyping PCR and sequencing of the transpeptidase domain of the ftsI gene were performed as described previously [11]. DNA sequences were analysed using Lasergene software (DNASTAR, Madison, WI, USA) and the sequences (nucleotides 1010–1719) have been deposited in the EMBL Lonafarnib nmr Nucleotide Sequence Database [EMBL:HG818627-818822].

An UPGMA (unweighted pair group method with arithmetic mean) phylogram of ftsI alleles from this and a previous study [11] was constructed by distance methods using ClustalW2 (http://​www.​ebi.​ac.​uk) and displayed using TreeDyn software (http://​www.​phylogeny.​fr) with H. parainfluenzae [EMBL:AB267856] as outgroup (Figure 2). Clusters of closely related alleles were assigned Greek letters (alpha – pi) with numbers denominating alleles within each cluster. Figure 2 ftsI phylogram. UPGMA phylogram of ftsI DNA sequences (transpeptidase domain, nucleotides 1010–1719) in the current (n = 196) and previous study (n = 46) [11]. The outgroup (Hpar) is H. parainfluenzae [EMBL:AB267856] and the reference sequence (z0) is H.

M. this website avium and Mycobacterium intracellulare have been recovered from various sources, including fresh water [9–13] and hospital water supplies, in which FLA are frequently isolated [14–17]. Several experimental studies have further demonstrated M. avium-FLA interactions, including Acanthamoeba spp. [3, 18–22] and Dictyostelium spp. [23–25]. M. avium and M. intracellulare have also been grown in the ciliated, unicellular protist Tetrahymena pyriformis [26]. It has been demonstrated that M. avium subsp. avium and M. avium subsp. paratuberculosis are able to survive within FLA [20–22], which results in their increased virulence [18, 19] and protection

against adverse situations including exposure to antibiotics [19]. The habitat of the recently described

Mycobacterium chimaera (formerly sequevar MAC-A), isolated from respiratory tract specimens [27–29]; Mycobacterium colombiense (formerly sequevar MAC-X), isolated from the blood of an HIV-positive patient [30] and from enlarged lymph nodes in non-immunocompromised Caspase inhibition children [30–32];Mycobacterium arosiense isolated from bone lesions [33]; and Mycobacterium marseillense, Mycobacterium timonense and Mycobacterium bouchedurhonense isolated from respiratory tract specimens [34, 35], remains however unknown. MAC species exhibit on-going evolutionary divergence as evidenced by the 97.9-98.71% ANI (Average Nucleotide Identity) between the genomes of M. avium subsp. paratuberculosis K10 (NC_000962) and M. avium strain 104 (NC_008595), the 3.7% 16S rRNA gene divergence between M. avium and M. timonense and between M. avium and M. chimaera, and the 7.2% rpoB gene sequence divergence between M. avium and M. colombiense [34]. Table 1 Studies of interactions between MAC species and amoeba. Mycobacterium avium Species Strains Amoeba species Survival in A. polyphaga Reference       Trophozoites Cysts

  M. avium subsp. avium M. avium most 109 A. castellanii + ? [47] M. avium subsp. avium CIP104244T A. polyphaga Linc-AP1 + + [3] M. intracellulare CIP104243T A. polyphaga Linc-AP1 + + [3] M. avium subsp.           paratuberculosis ? A. castellanii CCAP1501 + ? [22] M. avium subsp.           paratuberculosis ? A. castellanii CCAP1501 + + [20] M. avium subsp. avium ? D. discodium AX2 + ? [24] M. avium subsp. avium ? A. castellanii + ? [48] M. avium subsp. hominissuis M. avium 104 A. castellanii ATCC30234 + ? [49] M. avium Serotype 4 A. castellanii ATCC30872 + + [21] M. avium ? A. castellanii ATCC30234 + + [18] M. avium subsp. avium ATCC 25291T A. polyphaga Linc-AP1 + + Present study M. avium subsp.           paratuberculosis ATCC 19698T – + + – M. avium subsp. hominissuis IWGMT 49 – + + – M. avium subsp. silvaticum ATCC 49884T – + + – M. intracellulare ATCC 15985 – + + – M. chimaera DSM 446232T – + + – M. colombiense CIP 108962T – + + – M.

g., HindIII, EcoRI, and EcoRV) but unaffected by RNase. Thus, ZZ1 is a dsDNA phage (data not shown). The ZZ1 genome has a total length of 166,682 bp and a GC content

of 34.3%, which is slightly lower than that described for the A. baumannii ATCC 17978 strain (38%, accession number NC_009085). An initial NCBI nucleotide blast analysis (blastn) of the complete genome sequence indicated that ZZ1 shares limited similarities with other known phage nucleotide selleck compound sequences, which confirmed its status as a novel Acinetobacter phage species. The top 4 most similar sequences found were of the Acinetobacter phages Acj9 [GenBank: HM004124.1], Acj61 [GenBank: GU911519.1], Ac42 [GenBank: HM032710.1], and 133 [GenBank: HM114315.1]. The max scores were 4662 (50% of coverage, 89% of max ident), 4448 (45% of coverage, 87% of max ident), 2634 (34% of coverage, 94% of max ident), and 2210 (31% of coverage, 92% of max ident). The four Acinetobacter phages were recently deposited in GenBank and were previously annotated

as T4-like phages [18]. No other Acinetobacter phages were hit by blastn. In addition, Enterobacteria Vadimezan mouse phage T4 ranked tenth, and its max score was 1972 (28% of coverage, 83% of max ident), suggesting that the ZZ1 phage might be a new member of the T4-like phage family. A sequence search using the NCBI open reading frame (ORF) finder revealed a total of 402 putative ORFs of 50 or more codons in the ZZ1 genome that have limited similarity to other known phage proteins. Among them, 118 ORFs have the highest similarity to predicted ORFs from the Acinetobacter phage Acj9; 47 ORFs are most similar to predicted ORFs from the Acinetobacter phage Acj61; 18 ORFs most closely resemble predicted ORFs from the Acinetobacter phage 133; and only 13 ORFs have the Urease highest score with predicted

ORFs from the Acinetobacter phage Ac42. In addition, of the 402 ORFs, 105 ORFs showed homology with sequences in GenBank with annotated function; 244 ORFs had matches with uncharacterized entries; and the remaining 53 ORFs had no match to sequenced genes in the database. Discussion Phage therapy has been the subject of several recent reviews, and the present study reinforces the view that it is worth exploring [1, 2, 19]. To the best of our knowledge, the characterization of lytic phages of A. baumannii has rarely been studied, although Ackermann et al. [16, 20] described the classification of an A. baumannii phage, and Soothill et al. [1, 21] tested the efficacy of phage therapy for experimental A. baumannii infections in mice. In this study, we focused our efforts on the isolation and characterization of A. baumannii phages with potential for prophylactic/therapeutic use. Phages are thought to be found wherever bacteria thrive [22]. Acinetobacter spp.

The COMSTAT results for both the type 3 fimbriae mutant and type 1 and 3 fimbriae double mutant revealed much lower www.selleckchem.com/products/Everolimus(RAD001).html substratum coverage than the wild type. This indicates that type 3 fimbriae are most important for initial

cell-surface attachment. Furthermore, the lower amount of biomass and average thickness of the biofilms for the type 3 fimbriae mutants compared to the wild type and type 1 fimbriae mutant indicates that type 3 fimbriae also mediates cell-cell adherence in the biofilm. Our results confirm previous studies demonstrating that type 3 fimbriae are important for K. pneumoniae biofilm formation [29, 33]. Also in E. coli , the recently discovered ability to express type 3 fimbriae, mediated by conjugative plasmids, was found to profoundly enhance biofilm formation [16, 17]. Thus, type 3 fimbriae expression seems to generally promote biofilm formation in different bacterial species. We have previously established that type 1 fimbriae but not type 3 fimbriae are an essential virulence factor in K. pneumoniae urinary tract infections [18, 19]. The present study demonstrates how the impact of a specific virulence factor may vary significantly in different infection scenarios and host environments. Thus, although type 3 fimbriae may

not be significantly involved in development of uncomplicated UTIs, our results indicates that type 3 fimbriae may be a significant virulence factor in CAUTIs since they promote biofilm formation LGK-974 cost on inert surfaces. Understanding the mode of bacterial growth in vivo during Rebamipide infection is important in relation to future therapeutic measures. Conclusions In conclusion, the present work shows that type 3 fimbriae, but not type 1 fimbriae, mediate biofilm formation in K. pneumoniae C3091. As type 3 fimbriae promote adhesion to abiotic surfaces and biofilm formation in K. pneumoniae and other species, as shown here and by other studies [16, 17, 29, 33], type

3 fimbriae may generally play a significant role in development of catheter related infections such as CAUTIs. In this respect, the occurrences of conjugative plasmids encoding type 3 fimbriae in other species are worrisome. As the vast majority of K. pneumoniae isolates are able to express both type 1 and type 3 fimbriae [1], the use of epidemiological studies to elucidate the role of fimbriae in catheter associated K. pneumoniae infections is difficult. Thus further studies using catheterized in vivo infection models, are needed to further characterize the role of fimbriae in catheter related infections. Acknowledgements C. Struve was partially financed by Danish Research Agency Grant 2052-03-0013. We would like to thank Professor Søren Molin, Centre for Biomedical Microbiology, Technical University of Denmark, 2800 Lyngby, Denmark, for providing flow chamber facilities. References 1. Podschun R, Ullmann U: Klebsiella spp .

A PS is used by identifying co-variables in both groups to insert in the logistic regression model. Seven co-variables useful for the analysis were identified: age, sex, tumor progression, KPS, chemotherapy, seizure frequency Selleck SCH772984 at base visit, follow-up duration. The statistical analysis of efficacy

between treatment groups was applied using a General Linear Model for fixed factors (GLM), taking into consideration the following factors: 1) Treatment Group (OXC versus Traditional AEDs) 2) Visit (baseline versus final follow-up) 3) Interaction between Treatment Group and Visit. The PS was applied only for the analysis of efficacy between treatment groups, and not for the safety/tolerability comparison between groups. For the analysis of safety variables (drop-out incidence and total incidence of side effects) we used the Fisher Exact Test taking into consideration the number of patients who had left the study or who had had side-effects. The changes of SF from baseline to the final follow-up visit were evaluated using statistical analysis on the intent-to-treat (ITT) population (that is patients who had had at least one on-treatment visit with seizure counts). Results Traditional AED group Patient Profiles Patients’ demographic and clinical characteristic are depicted in table 1 [see additional file 1]. Sixteen (16) had had glioblastoma multiforme (GBM), 5 anaplastic

astrocytoma (AA), 4 anaplastic oligodendroglioma (AO), 8

low grade astrocytoma (LGA) and 2 low grade oligodendroglioma (LGO). Tyrosine Kinase Inhibitor Library screening Fourteen patients had undergone only chemotherapy during the follow up, 7 patient had undergone only radiotherapy, 11 chemotherapy and radiotherapy and 3 patients had not undergone any systemic therapy. Eight patients had had tumoral progression during follow up. The mean age at diagnosis of brain tumor was 50.1 years (range 22 to 76 years). Nine patient had had simple partial seizures (SP), 9 had had complex partial (CP), 3 had had SP + secondarily generalized tonic clonic seizures (SP+SGTC) and 14 had had CP+SGTC seizures. Patients had all been in monotherapy with traditional AEDs: PB (N = 24); CBZ (N = 9); VPA (N = 1), PHT (N Glycogen branching enzyme = 1). Mean dosages: PB = 112.5 mg/day, CBZ = 800 mg/day, VPA 1000 mg/day (only 1 patient), PHT 200 mg/day (only 1 patient) [see additional file 1]. Efficacy The mean seizure frequency per month before AED treatment had been 4.1 (35 patients) and 1.6 (35 patients) at final follow up. At final follow up, 45.7% of patients (16 patients) were seizure free. GLM repeated measure analysis showed a significant reduction of seizure frequency at final follow-up (p = 0.0095). Mean duration of follow up was 13.7 months (range 2 to 48 months). Adverse Events During treatment fifteen patients (42.9%) had reported side effects: 11 patients in therapy with PB, 3 with CBZ and 1 with VPA. Two patients (5.

Basal-like subtype is characterized by multigenetic signature, usually with high expression of high molecular weight cytokeratins normally expressed in basal myoepithelial cells: keratin 5 (CK5), 14 (CK14) and keratin 17 (CK17) [1, check details 2]. They usually express vimentin and p-cadherin, and more

than 60% of them also express epidermal growth factor receptor (EGFR) [3, 4]. A great interest in basal like-cancers produced attempts to determine basal-like tumors by the use of a much more easier technique such as immunohistochemistry. Unfortunately, both methods — oligonucleotide microarrays and immunohistochemistry – do not produce identical results. In the study by Nielsen and al., RG7204 molecular weight immunohistochemical panel for basal-like cancers

was defined as lack of ER and HER2 expression and positivity for CK5/6 or EGFR [5]. Unfortunately, this panel still presented only 76% sensitivity for basal-like tumors derived from a microarray study. Another attempt to simplify the determination of basal-like tumors was regarding them as synonymous with “”triple negative tumors”", regarded as lack of ER, PGR and HER2 [6]. But according to comparative studies, as much as 15-54% of basal-like tumors defined on mRNA level, still express at least one of these markers [4, 5, 7–9]. Quantitative real-time RT-PCR technology provides a precise assessment of even small changes in gene expression. In this aspect, real-time RT-PCR is a much more sensitive assay when compared with oligonucleotide microarray and could be considered as a referential method [10]. This raises the question whether microarray-based classification of breast tumors could be reconstructed or even improved by the use of data from the quantification

of expression of selected genes assessed by real-time RT-PCR. Recently, there have been published some data supporting this thesis [11]. In a previous study, we have compared ER expression estimated by RT-PCR and by a routine immunostaining, and have validated which method might be more reliable for the molecular subtyping in relation with basal-type keratins and HER2 genes expression [12]. Both methods produced discordant Selleckchem Ribociclib results in a proportion of cases, and lack of prognostic relevance of ER-mRNA level has been demonstrated, whereas the assessment by immunostaining has been related to clinical outcome. Also expression of basal keratins and HER2 genes significantly differed between ER-positive and ER-negative tumors divided on the basis of immunostaining, but not by mRNA level. Whereas immunostaining results are specific for tumor cells, mRNA for the RT-PCR analysis could originate not only from cancer cells but also from normal breast epithelium, myoepithelial and stromal cells. Furthermore, due to post-transcriptional and post-translational mechanisms, the amount of detected mRNA not always directly reflects protein level.

During polishing, the grits of abrasive paper squeeze the surface of the Cu foil and rub it into the rough surface which will leave a compressive residual stress on the surface of the learn more polished Cu foil specimen [25]. It can be found that Figure 7 has a similar shape with Figure 2, which indicates that the initial compressive stress on the specimen surface has a relationship with the density of FGLNAs grown on the specimen. It is considered that

initial compressive stress has an action to obstruct the volume expansion of the oxide layer which formed on the specimen surface during the heating process. Therefore, a higher effective VGS would occur for the same oxide volume expansion, which induces more and faster diffusion of Cu atoms to the specimen’s surface, thereby increasing the density of grown FGLNAs. On the other hand, the heating time for the first appearance of FGLNAs was also observed for the specimens of unpolished Cu foil, polished Cu foil (400 grit), and Cu film. As shown in Figure 8, the heating time for the specimens of unpolished Cu foil, polished Cu foil (400 grit), and Cu film is 3, 2, and

1.5 h, respectively. Compared with the results shown in Figure 7, higher initial compressive check details stress in the specimen leads to shorter heating time for the first appearance of FGLNAs. It indicates that higher vertical gradient stress promotes the diffusion of Cu atoms, thereby speeding up the growth of FGLNAs. Therefore, the same

heating time results in the highest density of FGLNAs grown on the Cu film specimen. Moreover, the thickness of the Ni catalyst can also affect the growth time of Cu2O FGLNAs but does not affect the morphology and size. Thinner thickness of the Ni film would lead to a longer time for the growth of FGLNAs. Figure 6 Ex situ θ /2 θ diffractograms measured for X-ray stress analysis. (a) Unpolished Cu foil, (b) polished Cu foil (400 grit), and (c) Cu film specimens before heating. The legend reports the corresponding ψ angles (i.e., inclination of the specimen). Figure 7 X-ray stress of unpolished Cu foil, polished Cu foil (400 grit), and Cu film specimens before heating. Figure 8 Heating time for the first appearance of FGLNAs. The FGLNAs were grown on the specimens of unpolished, polished Cu Osimertinib foils (400 grit), and Cu film. Figure 9 shows the XRD spectra of polished Cu foil (400 grit) and Cu film specimens before heating, and the peak width at half height was calculated using the JADE software (version 6.5). Mean grain size determined from the width of the diffraction peaks using Scherrer’s formula is 42 nm for the specimen of polished Cu foil and 59 nm for the Cu film specimen. It is considered that larger grain size may induce larger initial compressive stress in the specimen, thereby creating larger vertical gradient stress to promote the growth of FGLNAs. It should be noted that polishing would not change the crystal size of the Cu foil specimen.

Nutrition 2004, 20:669–677.CrossRefPubMed 7. Nieman DC, Davis JM, Henson D, Walberg-Rankin AJ, Shute MCL, Dumke AC, Utter DM, Vinci JA, Carson A, Brown WJ, Lee SR, Mcanulty A, Mcanulty LS: Carbohydrate ingestion influences skeletal muscle cytokine mRNA and plasma cytokine levels after a 3-h run. Journal of Applied Physiology 2003, 94:1917–1925.PubMed

8. Kjaer M: Hepatic glucose production during exercise. Advances in Experimental Medicine and Biology 1998, 441:117–27.PubMed 9. Mignini F, Traini E, Tomassoni D, Vitali M, Streccioni V: Leucocyte subset redistribution in a human model of physical stress. Clinical Experimental Hypertension 2008,30(8):720–31.CrossRef 10. Zarkovic Selleckchem XAV-939 M, Ignjatovic S, Dajak M, Ciric J, Beleslin B, Savic S, Stojkovic M, Bulat P, Trbojevic B: Y-27632 manufacturer Cortisol response to ACTH stimulation correlates with interleukin 6 concentration in healthy humans. European Journal of Endocrinology 2008,159(5):649–52.CrossRefPubMed 11. Rivier A, et al.: Release of cytokines by blood monocytes during strenuous exercise. International

Journal of Sports Medicine 1994, 15:192–198.CrossRefPubMed 12. Moldoveanu AI, et al.: Exercise elevates plasma levels but not gene expression of IL1 beta, IL-6, and TNF-alpha in blood mononuclear cells. Journal Applied Physiology 2000,89(4):1499–504. 13. Prestes J, De Ferreira CK, Dias R, Frollini AB, Donatto FF, Cury-Boaventura MF, Guereschi MG, Pithon-Curi TC, Verlengia R, Palanch AC, Curi R, Cavaglieri CR: Lymphocyte and Cytokines after Short Periods of Exercise. International Journal of Sports Medicine 2008, 29:1010–1014.CrossRefPubMed 14. Ostrowski K, et al.: Physical activity and plasma interleukin-6 in humans – effect of intensity of exercise. TCL European Journal of Applied Physiology 2000, 83:512–515.CrossRefPubMed 15. Pedersen BK, Steenberg A, Fischer C, Keller C, Keller P, Plomgaard P, Wolsk-Petersen E, Febbraio M: The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor? Proceeds

of Nutrition Society 2004, 63:263–267. 16. Pedersen BK: The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays Biochemistry 2006, 42:105–17.CrossRef 17. Cox AJ, Pyne DB, Saunders PU, Callister R, Gleeson M: Cytokine responses to treadmill running in healthy and illness-prone athletes. Medicine and Science in Sports and Exercise 2007,39(11):1918–1926.CrossRefPubMed 18. Puglisi MA, Vaishnav U, Shrestha SW, Torres-Gonzalex M, Wood RJ, Volek JS, Fernandez ML: Raisins and additional walking have distinct effects on plasma lipids and inflammatory cytokines. Lipids in Health and Disease 2008, 7:1–14.CrossRef 19. Caruso L, Menezes EW: Glycemic index of foods. Journal of Brazilian Society of Food and Nutrition 2000, 19:49–64. 20. Nieman DC, Pedersen BK: Nutrition and Exercise Immunology Boca Raton. FL: CRC Press; 2000. 21.

Michalski TJ, Hunt JE, Bowman MK, Smith U, Bardeen K, Gest H, Norris JR, Katz JJ: Bacteriopheophytin g: Properties and some speculations on a possible primary role for bacteriochlorophylls b and g in the biosynthesis of chlorophylls. Proc Natl Acad Sci USA 1987, 84:2570–2574.PubMedCrossRef 11. Dong MQ, Venable JD, Au N, Xu T, Park SK, Cociorva D, Johnson JR, Dillin A, Yates JR: Quantitative mass spectrometry identifies insulin signaling targets in C. elegans. Science 2007, 317:660–663.PubMedCrossRef 12. Overmann J: The family Chlorobiaceae . The Prokaryotes

2006, 7:359–378.CrossRef SCH 900776 in vivo 13. Evans MC, Buchanan BB, Arnon DI: New cyclic process for carbon assimilation by a photosynthetic bacterium. Science 1966, 152:673.PubMedCrossRef 14. Hugler M, Huber H, Molyneaux SJ, Vetriani C, Sievert SM: Autotrophic CO 2 fixation via the reductive tricarboxylic acid cycle in different lineages within the phylum Aquificae: evidence for two ways of citrate cleavage. Environ Microbiol 2007, 9:81–92.PubMedCrossRef 15. Schmitz RA, Daniel R, Deppenmeier U, Gottschalk G: The anaerobic way of life. The Prokaryotes 2006, 2:86–101.CrossRef 16. Kim W, Tabita

FR: Both subunits of ATP-citrate lyase from Chlorobium tepidum contribute to catalytic activity. J Bacteriol 2006, 188:6544–6552.PubMedCrossRef 17. Wahlund TM, Tabita FR: The reductive tricarboxylic check details acid cycle of carbon dioxide assimilation: initial studies and purification of ATP-citrate lyase from the green sulfur bacterium Chlorobium tepidum . J Bacteriol 1997, 179:4859–4867.PubMed 18. Pickett MW, Williamson MP, Kelly DJ: An enzyme and 13C-NMR of carbon metabolism in heliobacteria. Photosynth Res 1994, 41:75–88.CrossRef 19. Furdui C, Ragsdale SW: The role of pyruvate ferredoxin oxidoreductase in pyruvate synthesis during autotrophic growth by the Wood-Ljungdahl pathway. J Biol Chem 2000, 275:28494–28499.PubMedCrossRef 20. Thauer RK: Microbiology. A fifth pathway of carbon fixation. Science 2007, 318:1732–1733.PubMedCrossRef 21. Kimble LK, Stevenson

AK, Madigan MT: Chemotrophic growth of heliobacteria in darkness. FEMS Microbiol Lett 1994, 115:51–55.PubMedCrossRef Dimethyl sulfoxide 22. Castano-Cerezo S, Pastor JM, Renilla S, Bernal V, Iborra JL, Canovas M: An insight into the role of phosphotransacetylase (pta) and the acetate/acetyl-CoA node in Escherichia coli. Microb Cell Fact 2009, 8:54.PubMedCrossRef 23. Raymond J, Siefert JL, Staples CR, Blankenship RE: The natural history of nitrogen fixation. Mol Biol Evol 2004, 21:541–554.PubMedCrossRef 24. Kimble LK, Madigan MT: Nitrogen fixation and nitrogen metabolism in heliobacteria. Arch Microbiol 1992, 158:155–161.CrossRef 25. Howard JB, Rees DC: Structural Basis of Biological Nitrogen Fixation. Chem Rev 1996, 96:2965–2982.PubMedCrossRef 26. Fuhrer T, Fischer E, Sauer U: Experimental identification and quantification of glucose metabolism in seven bacterial species. J Bacteriol 2005, 187:1581–1590.PubMedCrossRef 27.

J Clin Invest 1996, 98:1954–1958.PubMedCrossRef 28. Schrager HM, Albertí S, Cywes C, Dougherty GJ, Wessels MR: Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes. J Clin Invest 1998, 101:1708–1716.PubMedCrossRef 29. Kawabata S, Kuwata H, Nakagawa I, Morimatsu S, Sano K, Hamada S: Capsular hyaluronic acid of group A streptococci hampers their invasion into human pharyngeal epithelial cells. Microb Pathog 1999, MK 1775 27:71–80.PubMedCrossRef 30. Darmstadt GL, Mentele L, Podbielski A, Rubens CE: Role of

group A streptococcal virulence factors in adherence to keratinocytes. Infect Immun 2000, 68:1215–1221.PubMedCrossRef 31. Saracatinib Stollerman GH, Dale JB: The importance of the group a streptococcus capsule in the pathogenesis of human infections: a historical perspective. Clin Infect Dis 2008, 46:1038–1045.PubMedCrossRef 32. Olsen RJ, Shelburne SA, Musser JM: Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol 2009, 11:1–12.PubMedCrossRef 33. Moses AE, Wessels MR, Zalcman K, Albertí S, Natanson-Yaron S, Menes T, Hanski E: Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus . Infect Immun 1997, 65:64–71.PubMed 34. Jiang SM, Ishmael N, Hotopp JD, Puliti M, Tissi L, Kumar N, Cieslewicz MJ, Tettelin H, Wessels

MR: Variation in the group B Streptococcus CsrRS regulon and effects on pathogenicity. J Bacteriol 2008, 190:1956–1965.PubMedCrossRef 35. Dalton TL, Scott JR: CovS inactivates Liothyronine Sodium CovR and is required for growth

under conditions of general stress in Streptococcus pyogenes . J Bacteriol 2004, 186:3928–37.PubMedCrossRef 36. Kreikemeyer B, Nakata M, Köller T, Hildisch H, Kourakos V, Standar K, Kawabata S, Glocker MO, Podbielski A: The Streptococcus pyogenes serotype M49 Nra-Ralp3 transcriptional regulatory network and its control of virulence factor expression from the novel eno ralp3 epf sagA pathogenicity region. Infect Immun 2007, 75:5698–5710.PubMedCrossRef 37. Podbielski A, Woischnik M, Leonard BA, Schmidt KH: Characterization of nra , a global negative regulator gene in group A streptococci. Mol Microbiol 1999, 31:1051–1064.PubMedCrossRef 38. Wessels MR, Bronze MS: Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. Proc Natl Acad Sci USA 1994, 91:12238–12242.PubMedCrossRef 39. Wessels MR, Goldberg JB, Moses AE, DiCesare TJ: Effects on virulence of mutations in a locus essential for hyaluronic acid capsule expression in group A streptococci. Infect Immun 1994, 62:433–441.PubMed 40. Bernish B, Rijn I: Characterization of a two-component system in Streptococcus pyogenes which is involved in regulation of hyaluronic acid production. J Biol Chem 1999, 274:4786–93.PubMedCrossRef 41.